Pramipexole in progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a progressive neurodegenerative dis order with no effective treatment. Dopaminergic agents occasionally produce transient symptomatic improvement. The authors report the results of prami pexole treatment (4.5 mg daily) in six patients with PSP (average disease d uration, 4.4 years). Patients were treated for 2 months. Patients were eval uated with the Unified Parkinson's Disease Rating Scale, Hoehn and Yahr sta ge, and Schwab and England Activities of Daily Living Scale at baseline and 2 months. Pramipexole was not efficacious for the symptoms of PSP.